ArticleDiscover oncology2025
Arginine methylation modulates tumor fate and prognosis in clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundArginine methylation, a key post-translational modification, plays a pivotal role in regulating various cellular processes and has been implicated in cancer progression. However, the potential of arginine methylation-related genes as prognostic markers in clear cell renal cell carcinoma (ccRCC) remains underexplored.
methodsWe utilized public transcriptomic datasets from TCGA, E-MTAB-1980 and ICGC, for model construction and validation. Single-cell RNA sequencing datasets were employed to evaluate gene expression patterns at the cellular level. Consensus clustering, KM survival analysis, and GSVA were applied to identify molecular subtypes and related pathways. Univariate and multivariate Cox regression analyses were applied to develop an arginine methylation-related signature (AMS). Immune profiling, mutation landscape, and drug sensitivity prediction were also employed to explore the model's association with clinical features, immune infiltration, mutation burden, and therapeutic responses.
resultsThe AMS demonstrated robust prognostic performance, with consistent validation across external cohorts. High-risk patients exhibited significantly worse survival, elevated TMB, and an immunosuppressive tumor microenvironment characterized by increased infiltration of regulatory immune cells. Single-cell RNA sequencing revealed key prognostic genes expressed predominantly in cancer and immune cells, supporting their role in tumor progression and immune interactions.
conclusionThe arginine methylation-based prognostic model provides a reliable framework for survival risk stratification in ccRCC and holds promise for guiding personalized therapeutic strategies. Future research should emphasize clinical validation of this model and explore its potential role in optimizing immunotherapy and targeted treatment strategies for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.